

October 11, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub : Clarification on reporting under Regulation 30 of SEBI (LODR) Regulations, 2015.

Ref : E-mail dated October 11, 2019 received from BSE

Further to the clarification sought by you on Unit-7 facility inspection by USFDA and issue of Form 483 with 7 observations, we inform that these observations have no impact on the existing business with respect to the operations and revenues. Hence, no disclosure was made earlier.

The Company will be sending responses to the observations within the stipulated time to the regulatory authority.

This is for your information and record.

Thanking you,

**Yours faithfully,
For AUROBINDO PHARMA LIMITED**



**B Adi Reddy
Company Secretary**



AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com